Diagnos Laboratorium Utama Stock Last Dividend Paid

DGNS Stock  IDR 220.00  4.00  1.79%   
Diagnos Laboratorium Utama fundamentals help investors to digest information that contributes to Diagnos Laboratorium's financial success or failures. It also enables traders to predict the movement of Diagnos Stock. The fundamental analysis module provides a way to measure Diagnos Laboratorium's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Diagnos Laboratorium stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Diagnos Laboratorium Utama Company Last Dividend Paid Analysis

Diagnos Laboratorium's Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.

Last Dividend

 = 

Last Profit Distribution Amount

Total Shares

More About Last Dividend Paid | All Equity Analysis
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
Competition

Based on the recorded statements, Diagnos Laboratorium Utama has a Last Dividend Paid of 0.0. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Diagnostics & Research (which currently averages 0.0) industry. This indicator is about the same for all Indonesia stocks average (which is currently at 0.0).

Diagnos Last Dividend Paid Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Diagnos Laboratorium's direct or indirect competition against its Last Dividend Paid to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Diagnos Laboratorium could also be used in its relative valuation, which is a method of valuing Diagnos Laboratorium by comparing valuation metrics of similar companies.
Diagnos Laboratorium is currently under evaluation in last dividend paid category among its peers.

Diagnos Fundamentals

About Diagnos Laboratorium Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Diagnos Laboratorium Utama's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Diagnos Laboratorium using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Diagnos Laboratorium Utama based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Other Information on Investing in Diagnos Stock

Diagnos Laboratorium financial ratios help investors to determine whether Diagnos Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diagnos with respect to the benefits of owning Diagnos Laboratorium security.